ERLEADA® (apalutamide)

 

As soon as you see a rapidly rising PSA in patients receiving ADT...

Push Back
on Progression

For Patients with Non-Metastatic CRPC in the spartan study

  • On ADT

  • With a rapidly rising PSA*

  • And no distant metastases detectable by conventional imaging

ERLEADA® + ADT improved median metastasis-free survival (MFS) by  2  YEARS  (24.3 months) vs placebo + ADT1

(40.5 months vs 16.2 months; HR=0.28; 95% CI: 0.23, 0.35; P<0.0001)

Review the Primary Publication for SPARTAN

Learn more about the results of the SPARTAN study in "Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer" published in The New England Journal of Medicine.

This article may only be available to subscribers of The New England Journal of Medicine (NEJM). To access this content, you may have to sign in using your personal or institutional credentials. If you are not registered or a member of NEJM, then you may need to purchase this article through their site.

Exploratory Analysis

Review the Patient-Reported Outcomes Publication for SPARTAN

Find out about patient-reported outcomes in “Effect of Apalutamide on Health-Related Quality of Life in Patients With Non-Metastatic Castration-Resistant Prostate Cancer: an Analysis of the SPARTAN Randomised, Placebo-Controlled, Phase 3 Trial” published in The Lancet Oncology.

This article may only be available to subscribers of The Lancet Oncology. To access this content, you may have to sign in using your personal or institutional credentials. If you are not registered or a member of The Lancet Oncology, then you may need to purchase this article through their site.

Janssen

Your One Source for Access, Affordability, and Treatment Support for Your Patients

Call a Janssen Care Coordinator at 877-CarePath (877-227-3728), Monday-Friday, 8:00 AM to 8:00 PM ET.

*PSA doubling time ≤10 months.

In the SPARTAN study, conventional imaging (technetium-99m bone scans and CT scans) was used to confirm that patients were non-metastatic at screening for inclusion. Patients with pelvic lymph nodes <2 cm in short axis (N1) located below the iliac bifurcation at screening were allowed in the study.2

ADT = androgen deprivation therapy; CI = confidence interval; CRPC = castration-resistant prostate cancer; CT = computed tomography; HR = hazard ratio; PSA = prostate-specific antigen; SPARTAN = Selective Prostate Androgen Receptor Targeting with ARN-509.

References

1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.

2. Smith MR, Saad F, Chowdhury S, et al; for the SPARTAN Investigators. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018;378(15):1408-1418.